Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 35Endocrine 35Gastrointestinal 7Genitourinary 3Thoracic 2CNS 2Lymphoid 1

Conditions

Carcinoma, Renal Cell 74Kidney Neoplasms 27Prostatic Neoplasms 16Neoplasm Metastasis 11Urinary Bladder Neoplasms 5Neoplasms 5Breast Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Carcinoma 4Neuroendocrine Tumors 3Carcinoma, Transitional Cell 3Adenocarcinoma 3von Hippel-Lindau Disease 2Triple Negative Breast Neoplasms 2Somatostatinoma 2Pheochromocytoma 2Margins of Excision 2Insulinoma 2Glucagonoma 2Gastrinoma 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Islet Cell 2Urothelial Cancer 1Ureteral Neoplasms 1Tuberous Sclerosis 1Thrombocytosis 1Testicular Neoplasms 1Renal Cell Cancer Metastatic 1Prostate Cancer Patients With Detectable PSA Following Prostatectomy 1Primary Myelofibrosis 1

Interventions

Magnetic Resonance Spectroscopy 3Everolimus 3atezolizumab 2Nivolumab 2Fluorodeoxyglucose F18 2FAPI-46 2tivozanib 1romidepsin 1pembrolizumab 1pasireotide 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1exemestane 1entrectinib 1cabozantinib 1alectinib 1Specimen Handling 1Respiratory Therapy 1Quality of Life 1Patient Reported Outcome Measures 1PT-100 dipeptide 1Neuropsychological Tests 1Molecular Diagnostic Techniques 1Lenalidomide 1Lactones 1LY2584702 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Everolimus × Genitourinary × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT01218555 2022-01-27

Study of Everolimus (RAD001) in Combination With Lenalidomide

Emory University

Phase 1 Completed
44 enrolled 9 charts
EndocrineGenitourinaryNET

Kidney Neoplasms, Neuroendocrine Tumors

NCT01115803 2019-02-05

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
29 enrolled 19 charts
EndocrineGenitourinaryNETThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡